On-Demand CME Videos
FC24: JAK to the Future: Advancing Alopecia Areata Care with Oral JAK Inhibitors: An Online Activity
About
JAK to the Future: Advancing Alopecia Areata Care with Oral JAK Inhibitors: An Online Activity
This activity is supported by educational grants from Sun Pharmaceutical Industries Ltd. and Lilly USA, LLC.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 2, 2024
December 2, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe the latest clinical evidence for the efficacy and safety of oral JAK inhibitors in the management of alopecia areata (AA).
Identify appropriate patients with AA for oral JAK inhibitors based on AA disease severity
Select appropriate dose adjustment strategies to optimize treatment of AA with oral JAK inhibitors
Review shared decision-making approaches to promote patient-centered care with oral JAK inhibitors
Intended Audience
Faculty
Carolyn Goh, MD
Associate Clinical Professor of Medicine-Dermatology
UCLA David Geffen School of Medicine
Los Angeles, CA
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Natasha Mesinkovska, MD, PhD
Vice Chair, Clinical Research
University of California Irvine
Irvine, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Speakers’ Bureau or Honoraria: Pfizer, Inc.
Other Relationships: Royalty: BMJ BestPractices
Grant/Research Support: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio Biosciences, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, Inc.
Consultant: Almirall, AltruBio Inc., AnaptysBio, Apogee Therapeutics, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, EPI, Evommune, Inc., Facilitation of International Dermatology Education, Forte biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda,Trevi, and Verrica
Advisory Board: Pfizer, Lilly, Concert, Abbvie, Galderma
Grant/Research Support: Pfizer
Consultant: National Alopecia Areata Foundation
Speakers’ Bureau or Honoraria: Lilly
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.